Objective-Although the investigation on the importance of mitochondria-derived reactive oxygen species (ROS) in endothelial function has been gaining momentum, little is known on the precise role of the individual components involved in the maintenance of a delicate ROS balance. Here we studied the impact of an ongoing dysregulated redox homeostasis by examining the effects of endothelial cell-specific deletion of murine thioredoxin reductase 2 (Txnrd2), a key enzyme of mitochondrial redox control. Approach and Results-We analyzed the impact of an inducible, endothelial cell-specific deletion of Txnrd2 on vascular remodeling in the adult mouse after femoral artery ligation. Laser Doppler analysis and histology revealed impaired angiogenesis and arteriogenesis. In addition, endothelial loss of Txnrd2 resulted in a prothrombotic, proinflammatory vascular phenotype, manifested as intravascular cellular deposits, as well as microthrombi. This phenotype was confirmed by an increased leukocyte response toward interleukin-1 in the mouse cremaster model. In vitro, we could confirm the attenuated angiogenesis measured in vivo, which was accompanied by increased ROS and an impaired mitochondrial membrane potential. Ex vivo analysis of femoral arteries revealed reduced flow-dependent vasodilation in endothelial cell Txnrd2-deficient mice. This endothelial dysfunction could be, at least partly, ascribed to inadequate nitric oxide signaling. Conclusions-We conclude that the maintenance of mitochondrial ROS via Txnrd2 in endothelial cells is necessary for an intact vascular homeostasis and remodeling and that Txnrd2 plays a vitally important role in balancing mitochondrial
T he importance of precisely balanced levels of reactive oxygen species (ROS) for the regulation of endothelial function, as well as the influence of impaired ROS homeostasis in the initiation and progression of endothelial dysfunction, has gained increased attention in recent years. [1] [2] [3] Indeed, derailed endothelial cell (EC) function contributes to a multitude of vascular diseases, including atherosclerosis, 4 hypertension, 5 vascular inflammation, 6 and ischemia/reperfusion injury. 7 It is now well established that endothelial sources of ROS include a range of dihydronicotinamide adenine dinucleotide phosphate oxidases, xanthine oxidase, uncoupled endothelial nitric oxide synthase (eNOS), and complexes of the mitochondrial respiratory chain. [8] [9] [10] Because ECs can accommodate most of their energy demands by anaerobic glycolysis, they are equipped with fewer mitochondria than other, more dynamic cells. [11] [12] [13] Consequently, EC mitochondria and ROS derived thereof have largely been underestimated in the past. Yet, they should be regarded in their capacity as regulatory signaling molecules, making the precise regulation of their concentrations just as important. 14 Mitochondrial ROS are kept in check by superoxide dismutase, catalase, glutathione peroxidases and reductases, and enzymes belonging to the thioredoxin system. The latter consists of thioredoxin 2 (Txn2) and thioredoxin reductase 2 (Txnrd2) and, together with glutathione, controls the release of hydrogen peroxide (H 2 O 2 ) from the mitochondria in concert with peroxiredoxin 3. [15] [16] [17] The contribution of its single constituent, however, to mitochondrial ROS control and organelle function in the cardiovascular system and specifically in ECs is only beginning to be realized. 18 It has been shown that Txn2 is downregulated in ECs during an ischemic insult and that overexpression of the enzyme can limit the usually observed, subsequent increase in ROS levels, leukocyte infiltration, and apoptosis. 19 An ubiquitous overexpression of Txn2 can also limit angiotensin II-induced ROS increases, both by controlling ROS emission from the mitochondria and by regulating cytosolic dihydronicotinamide adenine dinucleotide phosphate oxidase subunit expression. 20 Nothing, however, is known on the role of the upstream enzyme, mitochondrial Txnrd2 in the vasculature or specifically in ECs, despite its vital importance, as demonstrated in other organs. 21 Thus, 2 mutations in the flavinadenine dinucleotide-binding domain of human TXNRD2 have been observed in some patients with dilated cardiomyopathy, 22 and we and associated laboratories have confirmed this enzyme's importance in the heart in a cardiomyocytespecific knockout mouse. 21, 23, 24 Having successfully generated a Tamoxifen-inducible, EC-specific Txnrd2 knockout mouse (Txnrd2 iECKO ), we hypothesized that elevated ROS originating from the mitochondria of ECs will affect general vascular function and impair vascular remodeling processes in a model of femoral artery ligation. Mice with an EC-specific deletion of Txnrd2 have delayed perfusion recovery after ligation of the femoral artery because of defects in both arteriogenesis in the adductor muscle and angiogenesis in the calf muscle. Interestingly, endothelial loss of Txnrd2 leads to increased vascular stiffness, impaired EC-dependent vasodilation, and a prothrombotic, proinflammatory vascular phenotype, which could be confirmed by an increased neutrophil response toward interleukin-1 in the mouse cremaster model. In vitro, we show that Txnrd2 deletion leads to elevated ROS and impairs the mitochondrial membrane potential.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Generation of Txnrd2 iECKO Mice and Confirmation of Gene Deletion
To address the role of mitochondrial ROS in the endothelium, we used mice with a conditional deletion of Txnrd2 in the endothelium. The breeding scheme for the generation of Txnrd2 iECKO mice is illustrated in Figure 1A and the genotyping in Figure 1B . Gene deletion induced by Tamoxifen was allowed to proceed for at least 4 weeks before the loss of Txnrd2 was confirmed in isolated renal ECs by immunoblotting ( Figure 1C ). No reduction of Txnrd2 expression was detectable in bone marrow tissue nor in CD45-positive cells derived thereof (n=5 per group; Figure IA and IB in the online-only Data Supplement). Endothelial deletion of Txnrd2 had no impact on survival under normal housing conditions nor was any obvious phenotype observed over a period of 18 months (maximal observation period; n=10 per group).
Loss of Txnrd2 in the Endothelium Impairs Both Angiogenesis and Arteriogenesis
Because of the absence of an overt phenotype in Txnrd2 iECKO mice, we subsequently investigated whether Txnrd2 is essential for angiogenesis and arteriogenesis induced by femoral artery ligation. Laser Doppler imaging revealed a significantly attenuated perfusion recovery in Txnrd2 iECKO mice compared with control littermates. The impairment was evident 7 days (n=16 per group) as well as 14 days post ligation (n=4 per group) and persisted until the latest observation point, 21 days after ligation (n=4 per group; Figure 2A ). This reduced perfusion recovery suggests that mice deficient of Txnrd2 in their endothelium experience impaired vascular remodeling. Numeric data from laser Doppler imaging are listed in Table  V in the online-only Data Supplement.
To elucidate the importance of Txnrd2 for angiogenesis and arteriogenesis, both adductor and calf muscles were isolated and sectioned for histological assessment 7 days post ligation. The CD31-positive area, a measure of capillary density, was determined in the calf muscles. Angiogenesis was significantly impaired in Txnrd2 iECKO mice compared with control littermates (Txnrd2 control , n=9; Txnrd2 iECKO , n=8; Figure 2B ). In the adductor muscles, the increase in the wall area and wall thickness of collateral arterioles in response to enhanced blood flow after the occlusion of the femoral artery was significantly blunted compared with Txnrd2 control mice as was the increase in luminal diameter (n=5 Txnrd2 control , n=6 Txnrd2 iECKO ; Figure 2C -2E). Thus, these findings support our assumption that Txnrd2 iECKO mice are indeed incapable of sufficient vascular remodeling after an ischemic insult. All numeric data are listed in Table V in the online-only Data Supplement.
Vascular Function of Arteries Derived From Txnrd2 iECKO Mice Is Impaired
Intrigued by the attenuated capacity for vascular remodeling, we examined whether further parameters of vascular health are affected. Flow-dependent vasodilation was significantly impaired in femoral artery segments with EC deletion of Txnrd2, as reflected by a rightward shift in the flow/dilation . Preincubation of control vessel segments with Nω-nitro-L-arginine methyl ester (L-NAME) had the same effect on the vasodilatory response as the deletion of Txnrd2 ( Figure 3B ; n=6). No additional attenuation of flow-dependent dilation was achieved by L-NAME in Txnrd2-deficient vessel segments ( Figure 3C ; n=7). In contrast, there was no difference in the vasodilatory response to the maximal acetylcholine concentration between the groups. A summary of the vessel responses is displayed in Figure 3D . Interestingly, inhibition of nitric oxide (NO) production with L-NAME significantly reduced the vasodilatory capacity of Txnrd2 control vessels exposed to acetylcholine, but not in vessels of EC Txnrd2-deficient mice ( Figure 3D uses other, eNOS-independent vasodilatory pathways. To investigate elevated H 2 O 2 as a possible compensatory vasodilator, we performed a second series of experiments in which we pretreated femoral arteries from both genotypes with L-NAME in combination with Catalase. Indeed, the vasodilatory response toward acetylcholine was significantly impaired in vessels derived from Txnrd2 iECKO mice compared with those from Txnrd2 control animals. These results suggest that increased levels of H 2 O 2 might indeed compensate for the impaired NO-dependent vasodilation in Txnrd2 iECKO mice ( Figure IC in the online-only Data Supplement; n=6).
Txnrd2 Deficiency Renders the Endothelium Prothrombotic and Proinflammatory
During the histolopathological analysis of the adductor muscle, we unexpectedly observed the presence of thrombi within arterial vessels of Txnrd2 iECKO mice, which were absent in vessels derived from Txnrd2 control mice ( Figure 4A ). Further analysis showed that these deposits were not only present in remodeled collateral arterioles, but also in the femoral artery and collateral arterioles of sham-operated hindlimbs of mice lacking Txnrd2, but not in control mice ( Figure 4A ). Subsequent immunohistological analysis revealed that some of these vascular alterations are located on top of the endothelial lining ( Figure IIA in the online-only Data Supplement). We also observed the presence of CD45-positive cells between the endothelial layer and the basal membrane, suggesting that these mice may have a proatherogenic phenotype ( Figure 4B ). Furthermore, some deposits were fibrin-positive, indicating that the endothelium of Txnrd2 iECKO mice is prothrombotic as well ( Figure 4C ). To test whether these observations are restricted to the vasculature of skeletal muscle tissue or whether this is a more generalized vascular phenotype, we additionally analyzed renal tissue. Interestingly, periodic acid-Schiff staining revealed segmental intraluminal hyaline deposits within the glomerular capillaries of Tnxrd2 iECKO mice ( Figure 4D , top row). Immunohistochemistry using an antibody against fibrin confirmed these deposits as microthrombi ( Figure 4D , bottom row). Quantitative analysis revealed a significantly higher percentage of glomeruli with fibrin deposition in Txnrd2 iECKO mice ( Figure 4D ), suggesting that the prothrombotic phenotype is indeed global. Intrigued by these findings, we also investigated the adherence of leukocytes to and transmigration through the vessel wall in the cremaster muscle after intrascrotal stimulation with interleukin-1β.
Although the rolling flux of leukocytes ( Figure 5A different among the groups, significantly more cells adhered to the venule wall ( Figure 5B ) and transmigrated into the surrounding tissue ( Figure 5B ) in Txnrd2 iECKO mice than in Txnrd2 control mice (n=6 per group), implying that the loss of Txnrd2 in the endothelium renders the vascular wall susceptible to inflammatory processes. The numeric data are listed in Table V in the online-only Data Supplement.
Elevated ROS and Impending Mitochondrial Dysfunction After Txnrd2 Loss
Owing to the inherent difficulties to study the underlying cellular mechanisms in isolated ECs because of their strongly reduced proliferative characteristics, we opted to investigate the intracellular impact of the loss of Txnrd2 in embryonic endothelial progenitor cells (eEPCs) as substitutes.
Genotyping and protein expression of Txnrd2 was assessed regularly in 3 clones per group (Txnrd2 +/+ /Txnrd2 −/− ) and is exemplarily displayed for one clone per group in Figure 6A . Deficiency of Txnrd2 led to a significant elevation of intracellular ROS levels in eEPCs (n=50 per group; Figure 6B ). Considering that Txnrd2 is expressed predominantly in the mitochondrial matrix, we also measured the mitochondrial membrane potential as a marker of mitochondrial health. Indeed, mitochondrial membrane potential was considerably more positive, indicative of impending mitochondrial dysfunction, but not lost completely (n=13 per group; Figure 6C , left columns), in line with the fact that these cells remained viable. The complete loss of mitochondrial membrane potential after pharmacological disruption with carbonyl cyanide 3-chlorophenylhydrazone supported this finding ( Figure 6C , right columns). All numeric data are listed in Table V in the online-only Data Supplement.
Txnrd2 −/− eEPCs Display Decreased Angiogenic Properties In Vitro
Based on these in vitro findings, we investigated if the impaired angiogenesis in Txnrd2 iECKO mice could also be observed in Txnrd2 −/− eEPCs. In a tube formation assay, we observed significantly impaired sprouting of Txnrd2-deficient eEPCs compared with wild-type cells (n=4, 8-10 region of interest per experiment; Figure 6D ). Stable re-expression of an N-terminally FLAG-tagged full-length Txnrd2 in Txnrd2deficient eEPCs (addback) rescued the impaired sprouting capacity compared with Txnrd2 −/− control cells carrying an empty vector (mock; n=4), showing that the impairment of tube formation was indeed because of the loss of Txnrd2. The successful reconstitution of Txnrd2 expression in Txnrd2 −/− eEPCs was confirmed by immunoblotting ( Figure IIB in the online-only Data Supplement). All numeric data are listed in Table V in the online-only Data Supplement.
Discussion
In the present work, we analyzed how the perturbation of mitochondrial ROS control in ECs affects vascular homeostasis and vascular remodeling processes. We show here that EC-specific loss of the mitochondrial antioxidant Txnrd2 attenuates angiogenesis and arteriogenesis and negatively affects endothelial function.
Though our understanding of the functional involvement of ROS in the processes governing vascular remodeling is increasing, several studies have revealed conflicting data. On the one hand, it has been shown in mouse models that an increase in intrinsic ROS production is a necessity for adequate blood flow recovery during hindlimb ischemia. 25 Accordingly, ischemia-induced neovascularization was markedly enhanced in mice lacking nuclear factor erythroid 2-related factor 2, a positive regulator of antioxidant systems. 26 In line, a knockout of the ROS-producing gp91phox-containing dihydronicotinamide adenine dinucleotide phosphate oxidase resulted in reduced neovascularization after hindlimb ischemia, and blocking ROS production with the glutathione peroxidase mimetic Ebselen worsened the postischemic outcome. 25 More specifically, in regard to ROS levels in the endothelium, EC-specific catalase transgenic mice display significant reductions of intracellular H 2 O 2 levels and impaired blood flow recovery, capillary formation, and collateral remodeling after hindlimb ischemia. 27 Together, these studies suggest that an increase in ROS is beneficial and even essential for the re-establishment and maintenance of perfusion after an ischemic insult. In contrast to the above reports, however, it has also been shown that reducing ROS can actually improve exactly the same parameters. Thus, EC-specific transgenesis of the mitochondria-located antioxidant Txn2 resulted in significantly enhanced recovery after hindlimb ischemia, despite limiting the usual increase of ROS in response to ischemia. 19 In addition, this EC-specific Txn2 overexpression also improved EC function as a whole and reduced atherosclerotic lesions in apolipoprotein E-deficient mice. 28 In our study, the loss of Txnrd2 in ECs negatively affected endothelial function and attenuated vascular remodeling processes. Txnrd2 iECKO mice responded to femoral artery ligation with insufficient angiogenesis and arteriogenesis, culminating in reduced hindlimb perfusion recovery and accompanied by hallmarks of endothelial dysfunction, such as reduced flow-dependent vasodilation. Intriguingly, the response of Txnrd2 iECKO mice to femoral artery ligation was comparable to the above mentioned mice with an EC-specific overexpression of the antioxidant catalase, which is expressed in peroxisomes and absent in mitochondria of most mammalian cells. 27, 29 Although both Txnrd2 and catalase are critically involved in the detoxification of H 2 O 2 , [30] [31] [32] their different cellular localization seems to be crucial for their roles in vascular remodeling processes and EC function. In the case of the EC-specific catalase transgenic mice, the lowered H 2 O 2 levels might result in impaired vasoreactivity because H 2 O 2 acts as an endothelium-derived hyperpolarizing factor in mice. 33 On the other hand, after occlusion of a main upstream vessel, ECs of collateral vessels recognize changes in shear stress/ blood flow velocity and transmit signals to the interior of the cell. Subsequent cellular responses involving changes in cell morphology, cell function, and gene expression 34 include increases in the expression and activity of eNOS. 35 eNOS in turn produces NO, one of the factors involved in flow-dependent vasodilation. However, under conditions of enhanced ROS levels, NO production and activity can be blunted either by ROS-dependent eNOS uncoupling or by an increased formation of peroxynitrite, and both processes ultimately result in endothelial dysfunction. 10 Indeed, we observed an impaired response to alterations in flow in Txnrd2 iECKO mice compared with mice expressing Txnrd2 in their endothelium. Interestingly, in the presence of the NO synthase inhibitor L-NAME, the response of Txnrd2 control vessels was rightshifted to the level of Txnrd2 iECKO vessels, whereas there was no effect of L-NAME on the vessels lacking Txnrd2 in the endothelium. Moreover, the response to acetylcholine was blunted only in vessels derived from Txnrd2 control mice when L-NAME was present, whereas vessels from Txnrd2 iECKO mice maintained their vasodilatory capacity, indicating that mice lacking EC-specificTxnrd2 have changed to other, non-NOdependent vasodilatory mechanisms. Although these alternative mechanisms of vasorelaxation are already insufficient under the physiological stimulus of flow-dependent dilation, they seem inadequate in pathophysiological situations requiring perfusion recovery. Numerous reports in the literature have described a similar effect in eNOS-deficient mice. 33, [36] [37] [38] However, consensus has not been reached on the precise identity of the compensating entity. Depending on the method, strain, and vascular bed used, endothelium-derived hyperpolarizing factor-dependent dilation 33, 38 and other autacoids, 36 as well as the upregulation of neuronal NOS as an alternative source of NO, 37 have been proposed.
Although the similarities between our model and the eNOS-deficient mice are evident in regard to remodeling defects, the Txnrd2 iECKO mice also displayed fibrin-positive intraluminal cellular and acellular deposits in both large and small arterial vessels. Most interestingly, these were also present in the sham-operated hindlimb. In eNOS-deficient mice, such thrombus formation has only been described in aging mice which have thrombotic microangiopathy in the kidney. 39 In line, Txnrd2 iECKO mice also displayed a large number of glomeruli with fibrin depositions. ROS originating from the mitochondria has been described to render the endothelium prothrombotic and proinflammatory, [40] [41] [42] and oxidative stress has also been shown to lead to an opening of inter-endothelial junctions and to promote the migration of immune cells across the endothelial barrier. 43 In agreement, we observed inflammatory cells within the vascular wall in our model, and stimulation of an inflammatory reaction in the cremaster muscle by scrotal injection of interleukin-1 resulted in enhanced adherence of leukocytes to and transmigration through the vascular wall compared with Txnrd2 control mice, indicating that the endothelium of these mice is indeed prone to vascular inflammation.
In summary, we add important information on the role of the mitochondrial thioredoxin system specifically in ECs, showing that chronic elevation of ROS because of a deficiency of Txnrd2 impairs NO signaling, the response to flow-dependent vasodilation and vascular remodeling, and renders the endothelium proinflammatory and prothrombotic, which are all hallmarks of endothelial dysfunction. Furthermore, in light of the existing literature, the findings presented in the current study illustrate how diverse the impact of ROS can be. Acute bursts of ROS are essential for adequate cellular responses, and even chronic increases can often be adequately accommodated to maintain cellular normality. Having to compensate chronically elevated ROS, however, renders cells susceptible to oxidative stress on facing an additional ROS challenge, especially when antioxidant systems become overwhelmed, as we have shown here. Moreover, our data provide evidence that derailing mitochondrial antioxidant defense mechanisms affects not only the organelle or the individual cell but, rather, influences complex processes, such as global vascular function which are, up to now, not known to be associated with mitochondria. In conclusion, our observations highlight the need for future studies to address more than alterations in ROS levels when attempting to elucidate their contribution to physiological and pathological vascular processes. Rather, the ROS source must also be regarded differentially in individual cell types and even on the organelle level, especially in light of the still unmet need for the development of ROS and antioxidant-targeting drugs to combat chronic, ROS-dependent vascular diseases.
